Oncology Frontier ―癌薬物療法をめぐる最近の話題

出版社： 先端医学社
著者：
発行日： 1996-08-10
分野： 臨床医学：一般  >  癌/腫瘍一般
ISBN： 9784915892394
電子書籍版： 1996-08-10 （第1版第1刷）
電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

1,975 円(税込)

購入する

商品紹介

進化を続ける薬物療法の最新動向から新しい治療分野まで解説し、将来の癌治療への展望につながる必読の書。
進展著しい新規抗癌剤の開発状況ならびに今後の展望を紹介し、癌遺伝子治療、QOLの問題についても解説。最前線で癌治療に取り組む方々にとって研究の最新動向をコンパクトに把握できる一冊。癌腫別各論の第2部に先立つ総集編。

目次

  • 表紙
  • 序
  • 執筆者一覧
  • 目次
  • 1 / 薬剤の開発
  • <1> 癌化学療法の新たなターゲット
  • はじめに
  • 1 DNAトポイソメラーゼ
  • ―トポイソメラーゼ標的抗癌剤
  • ―トポイソメラーゼ標的薬剤の併用と新しい薬剤開発
  • 2 腫瘍血管新生
  • ―アンジオスタチン
  • ―真菌由来血管新生阻害物質 (AGM-1470/TNP470)
  • ―インターフェロン (IFN)-α
  • ―血小板因子4 (PF4)
  • ―スラミン
  • ―トロンボスポンジン
  • ―ビタミン
  • ―イルソグラジン
  • ―接着分子
  • おわりに
  • <2> 最近注目されている抗癌剤の開発
  • はじめに
  • 1 新規抗癌剤発見・開発
  • 2 注目されている抗癌剤
  • ―パクリタキセル (TXL)
  • ―ドセタキセル (TXT)
  • ―イリノテカン (CTP-11)
  • ―ビノレルビン (VNB)
  • ―ゲムシタビン (dFdc)
  • おわりに
  • <3> ホルモン療法に用いる薬剤の開発
  • はじめに
  • 1 主要ホルモン剤の作用
  • ―アンドロゲン
  • ―エストロゲン
  • ―その他ホルモン剤の作用について
  • 2 わが国における最近のホルモン剤の開発
  • ―抗アンドロゲン薬
  • ―抗エストロゲン薬
  • ―その他のホルモン剤
  • おわりに
  • 2 / 化学療法の進歩
  • <1> 抗癌剤のpharmacology -pharmacokineticsとphrmacodynamics-
  • はじめに
  • 1 pharmacokinetics[PK]とpharmacodynamics[PD]
  • ―pharmacokinetics (PK) とは
  • ―pharmacodynamics (PD) とは
  • ―PKにかかわる薬物輸送, 代謝酵素の人種的多様性, 薬物相互作用
  • ―作用機序よりみた抗癌剤のタイプ
  • 2 新規抗癌剤の臨床試験でのPK
  • ―前臨床試験におけるPK
  • ―新規抗癌剤の臨床試験でのPK
  • ―臨床第I/II相試験におけるPK/PD
  • ―大量化学療法の臨床試験でのPK
  • ―大量化学療法の際に使用される抗癌剤とそれらの単剤としてのPK
  • 3 標準的治療でのPKの適用
  • 4 母集団薬物動態学 (PPK)
  • ―PPKとは
  • ―NONMEM法
  • おわりに
  • <2> Biomodulation
  • はじめに
  • 1 biomodulationの概念
  • 2 臨床応用されているbiomodulationの実際
  • ―MTX/5-FU時間差投与法
  • ―LV/5-FU併用療法
  • ―CDDP/5-FU併用療法
  • ―BRM/5-FU併用療法
  • おわりに
  • <3> Dose intensive chemotheray
  • はじめに
  • 1 dose intensity [DI]について
  • 2 DIをおこなうための支持療法
  • ―コロニー刺激因子 (CSF)
  • ―末梢血幹細胞移植 (PBSCT)
  • ―自家骨髄移植 (ABMT)
  • 3 DIを考慮した化学療法
  • ―乳癌
  • ―小細胞肺癌
  • ―卵巣癌
  • ―胚細胞腫瘍
  • ―非ホジキンリンパ腫 (NHL)
  • おわりに
  • 3 / BRMの進歩
  • <1> 抗腫瘍免疫機構における非特異的免疫賦活剤の役割と新しい作用機序
  • はじめに
  • 1 ヒト癌における免疫療法の特徴
  • 2 抗腫瘍作用の特徴
  • 3 一般的な作用機序
  • ―OK-432
  • ―PSK
  • ―レンチナン
  • 4 ヒト癌に対する治療成績
  • ―OK-432
  • ―PSK
  • ―レンチナン
  • 5 新しい作用機序の解明
  • ―OK-432
  • ―PSK
  • ―レンチナン
  • 6 適応症例選択基準の探索
  • ―OK-432
  • ―PSK
  • ―レンチナン
  • 7 臨床評価法の妥当性
  • おわりに
  • <2> 癌のサイトカイン療法-IL-12を中心に-
  • はじめに
  • 1 IL-12の性状
  • 2 IL-12の抗腫瘍細胞性免疫に対する作用
  • 3 マウス実験モデルにおけるIL-12のin vivo抗腫瘍効果
  • 4 IL-12の癌遺伝子治療への応用
  • 5 IL-12の癌養子免疫療法 (Th1 ヘルパー/キラー療法) への応用
  • おわりに
  • <3> BRMとしてのレチノイド
  • はじめに
  • 1 レチノイド
  • 2 レチノイドの生物作用
  • ―レチノイド受容体
  • 3 レチノイドと癌
  • 4 レチノイドによる癌の再発抑制
  • 5 レチノイドによる積極的な癌治療に向けて
  • おわりに-遺伝子療法としてのレチノイド療法-
  • 4 / 薬剤耐性の克服
  • <1> P糖蛋白の関与する多剤耐性・関与しない多剤耐性
  • はじめに
  • 1 多剤耐性細胞の耐性遺伝子
  • 2 P糖蛋白の臨床発現と機能
  • 3 multidrug resistance-associated protein (MRP)
  • 4 DNAトポイソメラーゼ II (トポII)
  • おわりに
  • <2> それぞれの抗癌剤に個有の耐性機構
  • はじめに
  • 1 cis-diamminedichloroplatinum [II] シスプラチンまたはcis-DDP
  • 2 薬剤蓄積量の低下
  • 3 細胞内チオール
  • ―グルタチオン (GSH)
  • ―メタロチオネイン (MT)
  • 4 DNA修復
  • 5 トポイソメラーゼ阻害薬
  • ―トポI阻害薬
  • ―トポII阻害薬
  • 6 微小管に作用する薬剤
  • おわりに
  • 5 / 副作用対策
  • <1> 血液毒性
  • はじめに
  • 1 抗癌剤による白血球減少とその対策
  • ―抗癌剤による白血球減少時の感染予防
  • ―抗癌剤による白血球減少時の細菌感染
  • ―抗癌剤による白血球減少時の真菌感染
  • 2 抗癌剤による血小板減少とその対策
  • 3 抗癌剤による貧血とその対策
  • <2> 消化器毒性
  • はじめに
  • 1 口内炎
  • ―対策
  • 2 悪心・嘔吐
  • ―対策
  • ―現状
  • 3 下痢
  • ―対策
  • ―下痢につづく二次的な症状の対策
  • おわりに
  • 6 / 薬物療法とQOL
  • <1> 癌薬物療法とQOL
  • はじめに
  • 1 QOLの概念
  • 2 癌化学療法におけるQOL評価の視点
  • 3 QOL評価の特徴
  • 4 栗原班QOL質問票の特徴
  • おわりに
  • 7 / 遺伝子治療
  • <1> 癌に対する遺伝子治療のストラテジーと問題点
  • はじめに
  • 1 癌に対する遺伝子治療のストラテジー
  • 2 遺伝子導入法
  • 3 ヒトの癌に対する遺伝子治療の現状
  • 4 今後の課題
  • おわりに
  • <2> 免疫遺伝子治療の現況
  • はじめに
  • 1 遺伝子導入法の限界と免疫法への応用
  • 2 免疫遺伝子治療の対象となる癌
  • 3 免疫遺伝子治療の方法
  • ―免疫細胞への遺伝子導入
  • ―腫瘍細胞への遺伝子導入
  • 4 抗原提示細胞への抗原遺伝子導入
  • 5 腫瘍の免疫系からのエスケープとその対策
  • おわりに
  • 索引
  • 奥付

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

1 / 薬剤の開発

P.14 掲載の参考文献
1) 西條長宏 : 癌の分子治療の展開. 癌治療の新たな試み, 新編 I, 西條長宏編, 医薬ジャーナル社, 大阪, 1995, pp. 9-29
 
2) 有吉寛, 小川一誠 : 注目される抗癌剤. 癌治療の新たな試み, 新編 I, 西條長宏編, 医薬ジャーナル社, 大阪, 1995, pp. 29-48
 
3) 川上美菜, 草場仁志, 鳥越清之ほか : 薬剤耐性. 癌治療の新たな試み, 新編 I, 西條長宏編, 医薬ジャーナル社, 大阪, 1995, pp. 85-104
 
4) Ishida, R., Sato, M., Narita, T. et al. : Inhibition of DNA topoisomerase II by ICRF-193 induces poly- ploidization by uncoupling chromosome dynamics from other cell cycle events. J. Cell Biol. 126 : 1341-1351, 1995
 
5) Kotoh, K., Naito, A., Yokomizo, J. et al. : Increased expression of DNA topoisomerase II gene and collateral sensitivity to camptothecin in human cisplatin-resistant bladder cancer cells. Cancer Res. 54 : 3248-3252, 1995
 
6) Taniguchi, K., Kohno, K., Kawanami, K. et al. : Drug-induced down-regulation of topoisomerase I in human epidermoid cancer cells resistant to saintopin and camptothecins. Cancer Res. 56 : 2348-2354, 1996
PubMed
7) Niimi, S., Nakagawa, K., Sugimoto, Y. et at. : Mecha-nism of cross-resistance to a camptothecin analogue (CPT-11) in a human ovarian cancer cell line selected by cisplatin. Cancer Res. 52 : 328-333, 1992
 
8) Kubo, T., Kohno, K., Ohga, T. et al. : DNA topoisomerase IIα gene expression under transcriptional control in etoposide/teniposide-resistant human cancer cells. Cancer Res. 55 : 3860-3864, 1995
 
9) Matsuo, K., Kohno, K., Sato, S. et al. : Enhanced expression of the DNA topoisomerase II gene in response to heat shock stress in human epidermoid cancer KB cells. Cancer Res. 53 : 1085-1090, 1993
PubMed
10) Sugimoto, Y., Tsukahara, S., Oh, H. T. et al. : Decreased expression of DNA topoisomerase I in camptothecin-resistant tumor cell lines as determined by a monoclonal antibody. Cancer Res. 50 : 6925-6930, 1990
 
11) Folkman, J. : Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature Med. 1 : 27-31, 1995
PubMed
12) Weidner, N., Semple, J. P., Welgh, W. R. et al. : Tumor angiogenesis and metastasis : correlation in invasive breast carcinoma. N. Engl. J. Med. 324 : 1-8, 1991
 
13) 龍頭正浩, 自見政一郎, 小野眞弓ほか : 癌の浸潤および転移. 血管と内皮 5 : 241-250, 1995
 
14) 桑野信彦, 和泉弘人, 河野公俊ほか : 血管新生. 臨床腫瘍学, 有吉寛, 西條長宏, 福岡正博ほか, 日本臨床腫瘍研究会, 1996 (印刷中)
 
15) Karp, J. E. and Broder, S. : Molecular foundations of cancer : new targets for intervention. Nature Med. 1 : 309-320, 1995
PubMed
16) O'Reilly, M. S., Holmgern, L., Shing, Y. et al. : Angiotensin : a novel angiogenesis inhibitor that mediators the suppression of metastases by a Lewis lung carcihoma. Cell 79 : 315-328, 1994
 
17) Chen, C., Parangi, S., Tolentino, M. T. et al. : A strategy to discover circulating angiogenesis inhibitors generated by human tumors. Cancer Res. 55 : 4230-4233,1995
 
18) Ingber, D., Fujita, T., Kishimoto, S. et al. : Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature 348 : 555-557, 1990
PubMed
19) Taylor, S. and Folkman, J. : Protamine is an inhibitor of angiogenesis. Nature 297 : 307-312, 1982
PubMed
20) Good, D. J., Polverini, R. J. and Rastinejad, F. : A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc. Natl. Acad. Sci. USA 87 : 6624-6628, 1990
 
21) Weinstat-Saslow, D. L., Zabrenetzky, V. S., Van-Houtte, K. et al. : Transcription of thrombospondin complementary DNA into a human breast carcinoma cell line reduces primary tumor growth, metastatic potential, and angiogenesis. Cancer Res. 54 : 6504-6511, 1994
 
22) Oikawa, T., Hirotani, K., Ogasawara, H. et al. : Inhibition of angiogenesis by vitamin D3 analogues. Eur. J. Pharmacol. 178 : 247-250, 1990
PubMed
23) Ono, M., Kawahara, N., Goto, D. et al. : Inhibition of tumor growth and neovascularization by an anti-gastric ulcer agent, irsogladine. Cancer Res. 56 : 1512-1516, 1996
PubMed
24) Nguyen, M., Strubel, N. A. and Bischoff, J. : A role for sialyl lewis-X/A glycoconjugates in capillary morphogenesis. Nature 365 : 267-269, 1994
 
25) Brooks, P. C., Montgomery, A. M. P., Rosenfeld, M. et al. : Integrin αβ3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 79 : 1157-1164, 1994
 
P.22 掲載の参考文献
1) 五味克成 : 新薬の開発〔デザインと合成〕. Current review 癌化学療法1993~94, 西條長宏, 鶴尾隆編, 中外医学社, 東京, 1993, pp. 67-71
 
2) Chabner, B. A. : Anti cancer drugs. In : Cancer: Principle & Practice of Oncology, Fourth Edition. J. B. Lippincott Co., Philadelphia, 1993, pp. 325-340
 
3) Wani, M. C., Taylor, H. L., Wall, M. E. et al. : Plant antitumor agentes VI. The isolation and strucure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J. Am. Chem. Soc. 93 : 2325-2327, 1971
 
4) Nicolaou, K. C., Yang, Z., Liu, J. J. et al. : Total synthesis of taxol. Nature 367 : 630-634, 1994
PubMed
5) Weiss, R. B., Donehower, R. C., Wiernik, P. H. et al. : Hypersensitivity reactions from taxol. J. Clin. Oncol. 8 : 1263-1268, 1990
PubMed
6) Eisenhauer, E. A., ten Bokkel Huinink, W. W., Swenerton, K. D. et al. : European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer : high-dose versus low-dose and long versus short infusion. J. Clin. Oncol. 12 : 2654-2666, 1994
PubMed
7) 佃博, 西條長宏 : 新しい抗癌剤. 臨床腫瘍研究最前線- Direction of Medical Oncology-, 協和企画通信, 東京, No. 2, 1995
 
8) Ringe1, I. and Horwitz, S. B. : Studies with RP56976 (Taxotere) : a semisynthetic analogue of taxol. J. Natl. Cancer Inst. 83 : 288-291, 1991
PubMed
9) Gupta, E., Lesting, M. T., Mick, R. et al. : Metabolic fate of irinotecan in humans : correlation of glucuronidation with diarrhea. Cancer Res. 54 : 3723-3725, 1994
 
10) Negoro, S., Fukuoka, M., Masuda, N. et al. : Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small cell lung cancer. J. Natl. Cancer Inst. 83 : 1164-1168, 1991
PubMed
11) Taguchi, T., Wakui, A., Hasegawa, K. et al. : Phase I clinical study of CPT-11. Jpn. J. Cancer Chemother. 17 : 115-120, 1990
 
12) Ohe, Y., Sasaki, Y., Shinkai, T. et al. : Phase I study and pharmacokinetics of CPT-11 with 5-day continuous infusion. J. Natl. Cancer Inst. 84 : 972-974, 1992
PubMed
13) Ariyoshi, Y. : Over view of new anticancer drugs developed in Japan. In : Cancer Chemotherapy, Challenges for the Future, ed. by Kimura, K. et al., Vol. 9, Excerpta Medica, Tokyo, 1994, pp. 157-167
 
14) Niitani, H., Furuse, K., Fukuoka, M. et al. : Phase I clinical study on new vinca alkaloid derivative, KW-2307 (vinorelbine). Jpn. J. Cancer Chemother. 21 : 177-187, 1994
 
15) Furuse, K., Ohta, M., Fukuoka, M. et al. : Early phase II clinical study of KW-2307 in patients with lung cancer. Lung Cancer Section in KW-2307 Study Group. Jpn. J. Cancer Chemother. 21 : 785-793, 1994
 
16) Kubota, K., Furuse, K., Niitani, H. et al. : A late phase II study of navelbine (vinorelbine), a new vinca alkaloid derivative, in non-small cell lung cancer. Lung Cancer 7 (suppl.) : 117, 1991
 
17) Tominaga, T., Nomura, Y., Adachi, I. et al.: Late phase II study of KW-2307 in advanced or recurrent breast cancer. KW-2307 Cooperative Study Group (Breast Cancer Section). Jpn. J. Cancer Chemother. 21 : 809-816, 1994
PubMed
18) Le Chevalier, T., Brisgard, D., Douillard, J. Y. et al.: Landomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone inadvanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. 1. Clin. Oncol. 12: 360-367, 1994
 
19) Kusunoki, Y., Furuse, S., Niitani, H. et al.: Randomized phase II study of vinorelbine (VRB) vs vindesine (VDS) in previously untreated non-small cell lungcancer (NCSLC): -final results-. Proc. Am. Soc. Clin. Oncol. 14: 353, 1995
 
20) Abbruzzese, J. L., Grunewald, R., Weeks, E. et al.: Aphase I clinical, plasma and celluar pharmacology study of gemcitabine. J CIin. Oncol. 9: 491-498, 1991
 
21) Negoro, S., Fukuoka, M., Kurita, Y. et al.: Results ofphase II studies of gemcitabine in non-small cell lungcancer (NSCLC) . Proc. Am. Soc. Clin. Oncol. 13: 367, 1994
 
22) 有吉寛, 小川一誠: 注目される抗癌剤. 癌治療の新たな試み・新編I, 西條長宏編,医薬ジャーナル社, 大阪, 1995, pp. 29-48
 
P.29 掲載の参考文献
1) Swain, S. M. and Lippman, M. E.: Endocrine therapies of cancer. In: Cancer Chemotherapy, ed. by Chabner, B. A. and Collins, J. M., J. B. LipPincott Co., Philadelphia, 1990, pp. 59-109
 
2) Loewe, S. and Voss, H. E.: Der tand der erfassung des mannlichen sexualhormons. Klin. VVochenschr. 9: 481-487, 1930
 
3) Huggins, C. and Clark, P. J.: Quantitative studies of prostate secretion. 1. Exp. Med. 72: 747-761, 1940
PubMed
4) Gonzalez-Barcena, D., Perez-Sanchez, P., Ureta-Sanchez, P. et al.: Treatment of advanced prostatic carcinoma with D-Trp-b-LH-RH. Prostate 7: 21-30, 1985
 
5) Knauer, E.: Die Ovarien-Transplantation. Arch. Gynekol. 60: 322-375, 1900
 
6) Griffiths, C. T., Hall, T. C., Saba, Z. et al.: Preliminary trial of aminoglutethimide in breast cancer. Cancer 32: 31-37, 1973
PubMed
7) 古武敏彦: 酢酸ゴセレリン. 現代医療22: 439-443, 1990
 
8) Newling, D. W. W.: The response of advanced prostate cancer to a new nonsteroidal antiandrogen; results of a multicenter open phase II study of casodex. Eur. Urol. 3: 18-21, 1990
 
9) Akaza, H.: Arandomized phase II trial of flutamide vs chlormadinone acetate in previously untreated advanced prostatic cancer.Jpn. J. Clin. Oncol. 23: 178-185, 1993
 
10) 野村雍夫: 乳癌. 臨床と研究58: 3489-3494, 1981
 
11) 塚越茂: アフェマ (塩酸ファドロゾール) について. 癌と化学療法22: 1991-1997, 1995
 

2 / 化学療法の進歩

P.38 掲載の参考文献
1) Mutschler, E., Derendorf, H., Schafer-Korting, M. et al.: Pharmacogenetics. In: Drug Actions-Basic Principles and Therapeutic Aspects, Medpharm Scientific Publishers, Stuttgart, 1995, pp. 68-69
 
2) Relling, M V., Evans, W. E., Fonne-Pfister, R. et al.: Anticancer drugs as inhibitors of two polymorphic cytochrome P450 enzymes, debrisoquin and mephenytoin hydroxylase, in human liver microsomes. Cancer Res. 49: 68-71, 1989
PubMed
3) Damia, G. and D'Incalci, M.: Clinical pharmacokinetics of altretamine (review) . Clin. Pharmacokinet. 28: 439-448, 1995
 
4) Diasio, R. B., Beavers, T. L, Carpenter, J. T. et al.: Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidemia and severe 5-fluorouracil induced toxicity. J. Clin. Invest. 81: 47-51, 1988
PubMed
5) Rowinsky, E. K. and Donehower, R. C.: Paclitaxel(Taxol) . N. Engl. J. Med. 332: 1004-1014, 1995
PubMed
6) Royer, I., Monsarrat, B., Sonnier, M. et al.: Metabolism of docetaxel by human cytochromes P450: interactions with paclitaxel and other antineoplastic drugs. Cancer Res. 56: 58-65, 1996
PubMed
7) Perez, E. A., Hack, F. and Fletcher, T.: Sequence-dependent cytotoxicity of taxol and etoposide in lung and breast cancer cell lines. Proc. Am. Soc. Clin. Oncol. (abstract#1604) 14: 491, 1995
 
8) Bartlett, N. L., Lum, B. L., Fisher, G. A. et al.: Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance. J. Clin. Oncol. 12: 835-842, 1994
PubMed
9) Boote, D. J., Dennis, 1. F., Twentyman, P. R. et al.: Phase I study of etoposide with SDZ PSC833 as a modulator of multidrug resistance in patients with cancer. J. Clin. Oncol. 14: 610-618, 1996
 
10) Sasaki, Y., Ohtsu, A., Shimada, Y. et al.: Simultaneous administration of CPT-11 and fluorouraci1: alternation of the pharmacokinetics of CPT-11 and SN-38 in patients with advanced colon cancer. J. Natl. Cancer Inst. 86: 1096-1098, 1994
 
11) Fuse, E., Kobayashi, S., Sugiyama, Y. et al.: Application of pharmacokinetically guided dose escalation with respect to cell cycle phase specificity. J. Natl. Cancer Inst. 86: 989-996, 1994
PubMed
12) Mitsuhashi, Y., Inaba, M., Sugiyama, Y. et al.: In vitro measurement of chemosensitivity of human small cell lung and gastric canser cell lines toward cell cycle phase-nonspecific agents under the clinically equivalent area under the curve. Cancer 70: 2540-2546, 1992
 
13) Peck, C. C., Barr, W. H., Benet, L. Z. et al.: Conference report : opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development. Clin. Pharmacol. Ther. 51: 465-473, 1992
 
14) Collins, J. M., Grieshaber, C. K. and Chabner, B.: Pharmacologically guided phase I clinical trials based upon preclinical drug development J. Natl. Cancer Inst.: 83: 1321-1326, 1990
 
15) Collins, J. M., Zaharko, D. S., Dedrick, R. L. et al.: Potential roles for preclinical pharmacology in phase I clinical trials. Cancer Treat. Reports 70: 73-80, 1986
 
16) EORTC Pharmacokinetics and Metabolism Group: Pharmacokinetically guided dose escalation in phase I clinical trials. Commmentary and proposed guidelines. Eur. J. Cancer Clin. Oncol. 23: 1083-1087, 1987
PubMed
17) Mick, R. and Ratain, M. J.: Model-guided determination of maximum tolerated dose in phase I clinical trials : evidence for increased precision. J. Natl. Cancer Inst. 85: 217-223, 1993
PubMed
18) O'Quigley, J., Pepe, M. and Fisher, L.: Continual reassessment method: a practical design for phase I clinical trials in cancer. Biometrics 46: 33-48, 1990
 
19) Sheiner, L. B. and Beal, S. L.: Bayesian individualization of pharmacokinetics: simple implementation and comparison with non-Bayesian methods. J. Pharm. Sci. 71 : 1344-1348, 1982
PubMed
20) Jones, R. B. and Matthes, S.: Pharmacokinetics. In: High-Dose Cancer Therapy, Williams ＆ Wilkins, Baltimore, 1992, pp. 43-60
 
21) Johansen, M. J., Madden, T., Wood, J. G. et al.: Phase I pharmacokinetic study of multicycle high-dose carboplatin followed by peripheral blood stem cell infusion. Proceedings of 86th Annual Meeting of American Association for Cancer Research (Abstract #1395) 36: 234, 1995
 
22) Growshow, L. B., Jones, R. J., Brundrett, R. B. et al.: Pharmacokinetics of busulfan: correlation with venoocclusive disease in patients undergoing bone marrow transplantation. Cancer Chem. Pharmacol. 25: 55-61, 1989
 
23) Sanathanan, L. P., Peck, C. C., Temple, R. et al.: The randomized concentration-controlled trial: an evaluation of its sample size efficiency. Control. Clin. Trials 12: 780-794, 1990
 
24) Calvert, A. H., Newell, D. R., Gumbrell, L. A. et al.: Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J. Clin. Oncol. 7: 1748-1756, 1989
PubMed
25) Finley, R. S. and LaCivita, C. L.: Neoplastic disorders. In: Applied Therapeutics-the Clinical Use of Drugs, Applied Therapeutics Inc., Vancouver, 1992, Chapter 52
 
26) Sheiner, L. B. and Benet, L. Z.: Premarketing observational studies of population pharmacokinetics ofnew drugs. Clin. Pharmacol. Ther. 38: 481-487, 1985
 
27) Sheiner, L. B. and Beal, S. L.: Evaluation of methods for estimating population pharmacokinetic parameters. I. Michaelis-Menten model: routine clinical pharmacokinetic data. J. Pharmacokinet. Biopharm. 8: 553-571, 1980
 
28) Mandema, J. W., Verotta, D. and Sheiner, L. B.: Building population pharmacokinetic-pharmacodynamic models. J. Pharmacokinet. Biopharm. 20: 511-528, 1992
PubMed
29) Bruno, R., Hille, D., Thomas, L. et al.: Population pharmacokinetics/pharmacodynamics of docetaxel(taxotere) in phase II studies. Proc. Am. Soc. Clin. Oncol. (abstract#1471) 14: 457, 1995
 
P.47 掲載の参考文献
1) Biomodulation-癌薬物療法の新たな展開-. 太田和雄 監修, 塚越茂, 新津洋司郎, 佐々木常雄, 赤沢修吾編, 先端医学社, 東京, 1994
 
2) Advanced Colorectal Cancer Meta-Analysis Project: Meta-analysis of randomized trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer. J. Clin. Oncol. 12: 960-969, 1994
PubMed
3) 赤沢修吾, 大石孝, 斉藤健一: 高齢者大腸癌に対する化学療法. 老年消化器病5: 115-121, 1993
 
4) Kemeny, N.: Current approaches to metastatic colorectal cancer. Semin. Oncol. 21: 67-75, 1994
PubMed
5) 菅野康吉, 太田和雄, 田口鐵男ほか: 多施設共同研究によるl-leucovorin・5-FU併用療法の進行結腸・直腸癌に対する前期第II相試験. 癌と化学療法22: 627-637, 1995
 
6) 吉野正曠, 太田和雄, 栗原稔ほか: 多施設共同研究による大量l-leucovorin・5-FU併用療法の進行結腸・直腸癌に対する後期第II相試験 (東日本グループ) . 癌と化学療法22: 785-792, 1995
 
7) 小西孝司, 薮下和久, 田口鐵男ほか: 多施設共同研究によるl-leucovorin・5-FU併用療法の進行結腸・直腸癌に対する後期第II相試験. 癌と化学療法22: 925-932, 1995
 
8) 赤沢修吾, 太田和雄, 栗原稔ほか: 多施設共同研究によるl-Leucovorin・5-FU併用療法の進行胃癌に対する後期第II相試験. 日癌治誌30: 569-583, 1995
 
9) 竹田彬一, 田口鐵男, 太田潤ほか: 多施設共同研究によるl-Leucovorin・5-FU併用療法の進行胃癌に対する後期第II相試験. 癌と化学療法22: 903-910, 1995
 
10) 江崎泰斗, 中野修治: 5-FU/Cisplatin療法. 癌治療とBiomodulations, 漆崎一朗編, 医薬ジャーナル社, 大阪, 1994, pp. 119-126
 
11) Koizumi, W., Kurihara, M., Sasai, T. et al.: Aphase II study of combination therapy with 5'-Deoxy-5- fluorouridine and cisplatin in the treatment of advanced gastric cancer with primary foci. Cancer 72 : 658-662, 1993
 
12) Kurihara, M.: Chemotherapy in Gastric Cancer. In: Gastric Cancer, ed. by Nishi, M., Ichikawa, H., Naka・ jima, T. et al., Springer-Verlag, Tokyo, 1993, pp. 425-443
 
13) Wadler, S., Schwartz, E. K., Goldman, M. et al.: Fluorouracil and recombinant alfa-2a-interferon: an active regimen against advanced colorectal car・ cinoma. J. Clin. Oncol. 7: 1769-1775, 1989
 
14) Raderer, M. and Scheithauer, W.: Treatment of advanced colorectal cancer with 5-fluorouracil and interferon-α: an overview of clinical trials. Eur. J. Cancer 31A: 1002-1008, 1995
 
15) Moertel, C. G., Fleming, T. R., Macdonald, J. S. et al.: Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N. Engl. J. Med. 322: 352-358, 1990
PubMed
P.53 掲載の参考文献
1) Frei, E. III. and Canellos, G. P.: Dose: acritical factor in cancer chemotherapy. Am. J. Med. 69: 585-594, 1980
 
2) Green, J. A., Dawson, A. A. and Fell L. F.: Measurement of drug dosage intensity in MVPP in Hodgikin's disease. Br. J. Cin. Pharmacol. 9: 551-514, 1980
 
3) Hryniuk, W. and Bush, H.: The importance of dose intensity in chemotherapy of metastatic breast cancer. J. Clin. Oncol. 2: 1281-1288, 1984
PubMed
4) Hryniuk, W. and Levine, M. N.: Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. J. Clin. Oncol. 4: 1162-1170, 1986
PubMed
5) Levin, L. and Hryniuk, W.: The application of dose intensity to problems in chemotherapy of ovarian and endometrial cancer. Semin. Oncol. 14 (suppl.): 12-19, 1987
 
6) Hryniuk, W., Figueredo, A. and Goodyear, M.: Application of dose intensity to problems in chemotherapy of breast and colorectal cancer. Semin. Oncol. 14 (suppl.): 3-11, 1987
 
7) Klasa, R. J., Murray, N. and Coldman, A. J.: Dose-intensity meta-analysis of chemotherapy regimens in small cell carcinoma of the lung. J. Clin. Oncol. 9: 499-508, 1991
PubMed
8) Norton, L. and Simon, R.: Tumor size, sensitivity to therapy, and design of treatment schedule. Cancer Treat. Rep. 61: 1307-1317, 1977
PubMed
9) Miller, L. L.: The therapeutic utility of G-and GM- CSF in counteracting the bone marrow suppression of chemo- and radiotherapy. In: Educational Book of ASCO Meeting 34, 1993
 
10) Brecher, G. and Cronkite, E. P.: Post-radiation parabiosis and survival in rats. Proc. Soc. Exp. Biol. Med. 77: 292-294, 1951
PubMed
11) Goldman, J. M.,: Autografting cryopreserved buffy coat cells for chronic granulocytic leukemia in transformation. Exp. Hematol. 7 (suppl. 5): 389-397, 1979
 
12) Gianni, A. M., Bregni, M., Siena, S. et al.: Rapid and complete hempoietic reconstitution following combined transplantation of autologous blood and bone marrow cells. A changing role for high dose chemo- radio-therapy?Hematol. Oncol. 7: 139-148, 1989
 
13) Gianni, A. M., Bregni, M., Stern, A. C. et al.: Glanulocyte-macrophage colony-stimulating factor to harvest circulating haematopoietic stem cells for autotransplantation. Lancet ii: 580-584, 1989
 
14) Siena, S., Bregni, M., Brando, B. et al.: Flow cytometry for clinical estimation of circulating hematopietic progenitors for autologous transplantation in cancer patients. Blood 77: 400-409, 1991
 
15) Ross, A. A., Cooper, B. W., Lazarus, H. M. et al.: Comparison of tumor cell contamination in peripheral blood stem cell collections (PBSC) and bone marrow (Bm) in patients with advanced breast cancer (ABC): using immunocytochemistry (ICC) evidence for clonogenicity of occult metastases. Blood (suppl. 1): 235a, 1992
 
16) Moss, T. J., Sanders, D. G., Lasky, L. C. et al.: Contamination of peripheral blood stem cell harvest by circulating neuroblastoma cells. Blood 76: 1879-1883, 1990
PubMed
17) Tannock, I. F., Boyd, N. F., DeBoer, G. et al.: A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer. J. Clin. Oncol. 6: 1377-1387, 1988
PubMed
18) Budman, D. R, Wood, I. C., Henderson, A. H. et al.: Initial findings of CALGB 8541: a dose and doseintensity trial of cyclophosphamide (C), doxorubicine (A), and 5-fluorouracil (F) as adjuvant treatment of stage II, node+, female breast cancer. Proc. ASCO 11: 51, 1992
 
19) Dimitrov, N., Anderson, S., Fisher, B. et al.: Dose intensification and incereased total dose of adjuvant chemotherapy for breast cancer (BC): Findings from NSABP B-22. Proc. ASCO l3: 64, 1994
 
20) Bronchud, M. H., Howell, A., Crowther, D. et al.: The use of granulocyte colony-stimulating factor to increase the intensity of treatment with doxorubicinin patients with advanced breast and ovarian cancer. Br. J. Cancer 60: 121-125, 1989
 
21) Demetri, G. D., Younger, J., Shapiro, C. et al.: A phase I study of dose-intensified CAF chemotherapy with adjunctive r-metHuG-CSF (GCSF) in patients with advanced breast cancer. Proc. ASCO 11: 108, 1992
 
22) Antman, K. H.: Dose intensive adjuvant therapy in breast cancer. In: Educational Book of ASCO Meeting 80, 1994
 
23) Fukuoka, M., Takada, M., Masuda, N. et al.: Dose intensity weekly chemotherapy (CT) with or without recombinant granulocyte colony-stimulating factor (G-CSF) in extensive-stage (ES) small cell lung cancer (SCLC) Proc. ASCO 11: 290, 1993
 
24) Elias, A. D., Ayash, L., Frei III, E. et al.: Intensive combined modality therapy for limited-stage smallcell lung cancer. J. Natl. Cancer Inst. 85 : 559-566, 1993
 
25) Kaye, S. B., Lewis, C. R., Paul, J. et al.: Randomized study of two doses of cisplatin with cyclophosphamide in epithelial cancer. Lancet 340: 329-333, 1992
PubMed
26) McGuire, W. P., Hoskins, W. J., Brady, M. F. et al.: A phase III trial of dose intense (DI) versus standard dose (DS) cisplatin (DCCP) and cytoxan (CTX) in advanced ovarian cancer (AOC) . Proc. ASCO 11: 226, 1992
 
27) Ozols, R. F., Ihde, D. C., Linehan, W. M. et al.: A randomized trial of standard chemotherapy v a high-dose chemotherapy regimen in the treatment of poor prognosis nonseminomatous grem-cell tumors. J. Clin. Oncol. 6: 1031-1040, 1988
 
28) Samson, M. K., Rivkin, S. E., Jones, S. E. et al.: Dose response and dose survival advantage for high versus low-dose cisplatin combined with vinblastine and bleomycin in disseminated testicular cancer. A Southwest Oncology Group Study. Cancer 53: 1029-1035, 1984
 
29) Nichols, C. R, Williams, S. D., Loehrer, P. J. et al.: Randomized study of cisplatin dose intensity in poor risk germ cell tumors: a Southeastern Cancer Study Group and Southwest Oncology Group Protocol. J. Clin. Oncol. 9: 1163-1172, 1991
 
30) Fisher, R. I., Gaynor, E. R., Dahlberg, S. et al.: Comparison of a standard regimen (CHOP) with three intensive chemothrapy regimens for advanced non-Hodgikin's lymphoma. N. Engl. J. Med. 328: 1002-1006, 1993
 

3 / BRMの進歩

P.60 掲載の参考文献
1) 鯉江久昭, 折田薫三, 細川真澄男ほか: 癌免疫外科宿主要因検討委員会報告. Biotherapy 5: 1561-1574, 1991
 
2) Van der Bruggen, P., Traversari, C., Chomez, P. et al.: A gene encoding an antigen recognized by cytotoxic T lymphocytes on a human melanoma. Science 264: 1463-1467, 1991
 
3) 小林博: がんの治療. 岩波新書, 岩波書店, 東京, 1993, p. 218
 
4) 佐治重豊: 癌転移における免疫療法の役割. Skin Cancer 4: 297-312, 1989
 
5) Maehara, Y., Okuyama, T., Kakeji, Y. et al.: Postoperative immunochemotherapy including streptococcal lysate OK-432 is effective for patients with gastric cancer and serosal invasion. Am. J. Surg. 168 : 36-40, 1994
PubMed
6) Tanaka, N., Gouchi, A., Ohara, T. et al.: Intratumoral injection of a streptococcal preparation, OK-432, before surgery for gastric cancer. Cancer 74: 3097-3103, 1994
PubMed
7) Nakazato, H., Koike, A., Saji, A. et al.: Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Lancet 343: 1122-1226, 1994
 
8) 三富利夫, 土屋周二, 飯島登ほか: 結腸・直腸癌の治癒切除症例に対するPSKによる補助免疫化学療法のrandomized controlled study. 癌と化学療法16: 2241-2249, 1989
 
9) 種村広巳, 佐治重豊, 宮喜一ほか: 進行再発胃癌に対するレンチナンを用いた免疫化学療法の有用性に関する共同研究. Biotherapy 10: 60-65, 1996
 
10) 山口佳之, 宮原栄治, 檜原淳ほか: OK-432免疫療法のresponderの探索と作用機序の解明. Biotherapy 10: 42-49, 1996
 
11) 杉山保幸, 佐治重豊, 国枝克行ほか: PSKの作用機序. Biotherapy 10: 18-25, 1996
Medical*Online
12) 海老名卓三郎: PSKの腫瘍免疫増強機序. Biotherapy 10 : 26-32, 1996
 
13) 羽室淳爾, 磯村俊郎, 鈴木学: Lentinanの新しい適応法についての基礎からの提言. Biotherapy 10: 72-82, 1996
 
14) 杉山保幸, 石原和浩, 李宗一ほか: BRM製剤のアポトーシス誘導能に関する基礎的検討. Biotherapy 10: 292-295, 1996
Medical*Online
15) Ogoshi, K., Mitomi, T., Tsuji, K. et al.: HLA antigen status and outcome of postoperative adjuvant immunochemotherapy in gastric cancer: a multidimensional data analysis. Ann. Cancer Res. Ther. 2: 95-99, 1993
 
P.68 掲載の参考文献
1) Kobayashi, M., Fitz, J., Ryan, M. et al.: Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biological effects on human lymphocytes. J. Exp. Mcd. 170: 827-845, 1989
 
2) Merberg, D. M., Wolf, S. F. and Clark, S. C.: Sequence similarity between NKSF and the IL-6/G-CSF family. Immunol. Today 13: 77-79, 1992
PubMed
3) Bacon, C. M., Petricoin, E. F. III, Ortaldo, J. R. et al.: Interleukin 12 induces tyrosine phosphorylation and activation of STAT 4 in human lymphocytes. Proc. Natl. Acad. Sci. USA92: 7307-7311, 1995
 
4) Chua, A. 0., Chizzonite, R., Desai, B. B. et el.: Expression cloning of a human IL-12 receptor component A new member of the cytokine receptor super-family with strong homology to gp130. J.Immunol. 153: 128-136, 1994
 
5) Nishimura, T., Watanabe, K., Hahata, T. et al.: Phenotypic and functional characterization of in vivo-induced interleukin-12-activated killer cells. Immunol. Lett. 48: 167-174, 1995
 
6) Lee, U., Santa, K., Habu, S. et al.: Murine asialo GM1+CD8+T cells as novel interleukin-12-responding killer T cell precursors. Jpn. J. Cancer Res. 87: 429-432, 1996
 
7) Hashimoto, W., Takeda, K., Anzai, R. et al.: Cytotoxic NK1.1 Ag+αβT cells with intermediate TCR induced in the liver or mice by IL-12. J. Immunol. 154: 4333-4340, 1995
 
8) Kuge, S., Watanabe, K., Makino, K. et al.: Interleukin-12 augments the generation of autologous tumor-reactive CD8+ cytotoxic T lymphocytes (CTL) from tumor-infiltrating lymphocytes. Jpn. J. Cancer Res. 86 : 135-139, 1995
PubMed
9) Trinchieri, G.: Interleukin-12: acytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cell type 1 and cyototoxic lymphocytes. Blood 84: 4008-4027, 1995
 
10) Nishimura, T., Watanabe, K., Lee, U. et al.: Interleukin-12 induces a tumor-specific protective immunity and inhibits both transplantable and primary tumor growth in vivo. (submitted)
 
11) Zou, J.-P., Yamamoto, N., Fujii, T. et al.: Systemic administration of rIL-12 induces complete tumor regression and protective immunity: response is correlated with a striking reversal of suppressed interferon-γ production by anti-tumor T cells. Int. Immunol. 7: 1135-1145, 1995
 
12) Nishimura, T., Watanabe, K., Yahata, T. et al.: Application of interleukin 12 to antitumor cytokine and gene therapy. Cancer Chemother. Pharmacol. (in press) 1996
 
13) Tahara,
 
14) Nishimura, T., Watanabe, K., Yahata, T. et al. The application of IL-12 to cytokine and gene therapy of tumor. Interleukin l2 : cellular and molecular immunology of an important regulatory cytokine. Ann. NY. Acad. Sci. USA (in press) 1996
 
15) Noguchi, Y., Richard, E, Chen, Y.-T. et al.: Influence of interleukin 12 on p53 peptide vaccination against established Meth A sarcoma. Proc. Natl. Acad. Sci. USA 92: 2219-2223, 1995
 
P.77 掲載の参考文献
1) Sporn, M. B., Robert, A. B. and Goodman, D. S. (eds.) The Retinoids. 2nd ed., Raven Press, New York, 1994
 
2) Livrea, M. A. and Vida1, G. (eds.): Retinoids: from Basic Science to Clinical Applications. Birkhaser, Basel, 1994
 
3) Hofmann, C. and Eichele, G.: Retinoids in development. In: The retinoids, 2nd ed., ed. by Sporn, M. B., Robert, A. B. and Goodman, D. S., Raven Press, NewYork, 1994, pp. 387-442
 
4) Lippmann, S. M., Kessler, J. F. and Meyskens, F. L: Retinoids as preventive and therapeutic anticancer agents (Part 1) . Cancer Treat. Rep. 71: 391, 1987
 
5) Gudas, L. J., Sporn, M. B. and Robert, A. B.: Cellularbiology and biochemistry of the retinoids. In: The Retinoids, 2nd ed., ed. by Sporn, M. B., Robert, A. B. and Goodman, D. S., Raven Press, New York, 1994, pp. 443-520
 
6) Mangelsdorf, D., Thummel, C., Beato, M. et al.: The nuclear superfamily: the second decade. Cell 83: 835, 1995
PubMed
7) Mangelsdorf, D. and Evans, R. M.: The RXR heterodimers and orphan receptors. Cell 83: 841, 1995
 
8) Kastner, P., Mark, M. and Chambon, P.: Nonsteroid nuclear receptors: what are genetic studies telling usabout their role in real life?Cell 83: 859, 1995
 
9) Breitman, T. R., Selonick, S. E. and Collins, S. J.: Induction of differentiation of the humanpromyelocytic leukemia all line (HL-60) by retinoic acid. Proc. Natl. Acad. Sci. USA 77: 2936, 1980
 
10) Hong, W. K., Lippman, S. M. et al.: Prevention ofsecond primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N. Engl. Med. 323: 795, 1990
 
11) Muto, Y., Moriwaki, H. et al.: Prevention of secondprimary tumors by an acyclic retinoid, polyprenoicacid, in patients with hepatocellular carcinoma. N. Engl. J.Med. 334: 1561, 1996
 
12) Huang, M. E., Ye, Y. -C., Chen, R.-S. et al.: Use of all- trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 72: 567, 1988
 
13) Ohno, R.: Differentiation therapy of myelodysplastic syndromes with retinoic acid. Leuk. Lymphoma 14: 410, 1994
 
14) Takeshita, A., Shibata, Y., Shinjo, K. et al.: Successful treatment of replace of acute promyelocytic leukemia with a new synthetic retinoid, Am 80. Ann. Intern. Med. 124: 893, 1996
 
15) Miller, V. A., Rigas, J. R. et al.: Initial clinical trialof the retinoid receptor par agonist 9-cis retinoic acid. Clin. Cancer Res. 212: 471, 1996
 
16) Shalinsky, D. R., Bischoff, E. D. et al.: Enhance antitumor efficacy of cisplatin in combination with ALRT 1057 (9-cis-retinoc acid) in human oral squamous carcinoma xenograft in nude mice. Clin. Cancer Res. 212, 1996
 
17) abstracts of AACR meeting, 1996
 
18) 日本癌学会総会記事,1995
 

4 / 薬剤耐性の克服

P.82 掲載の参考文献
1) Tsuruo, T.: Mechanism of multidrug resistance and implications for therapy. Jpn. J. Cancer Res. 79: 285-296, 1988
PubMed
2) Chen, C. -J., Chin, J. E., Ueda, K. et al.: Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell 47: 381-389, 1986
PubMed
3) Gerlach, J. H., Endicott, J. A., Juranka, P. F. et al.: Homology between P-glycoprotein and a bacterial haemolysin transport protein and a bacterial haemolysin transport protein suggests a model for multidrug resistance. Nature 324: 485-489, 1986
 
4) Fojo, A. T., Ueda, K., Slamon, D. J. et al.: Expression of a multidrug-resistance gene in human tumors and tissues. Proc. Natl. Acad. Sci. USA 84: 265-269, 1987
PubMed
5) Thiebaut, F., Tsuruo, T., Hamada, H. et al.: The location of the multidrug resistance gene-product P-glycoprotein in normal tissues. Proc. Natl. Acad. Sci. USA 84: 7735-7738, 1987
PubMed
6) Sugawara, I., Kataoka, I., Morishita, Y. et al.: Tissue distribution of P-glycoprotein encoded by a multidrug-resistant gene as revealed by a monoclonal antibody, MRK16. Cancer Res. 48: 1926-1929, 1988
 
7) Thorgeirsson, S. S., Huber, B. E. and Sorrelli, S.: Expression of the multidrug-resistant gene in hepatocarcino-genesis and regenerating rat liver. Science 236: 1120-1122, 1987
 
8) Tatsuta, T., Naito, M., Oh-hara, T. et al.: Functional involvement of P-glycoprotein in blood-brain barrier. J. Biol. Chem. 267: 20383-20391, 1992
 
9) Cole, S. P., Bhardwaj, G., Gerlach, J. H. et al.: Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258: 1650-1654, 1992
 
10) Cole, S. P., Sparks, K. E., Fraser, K. et al.: Phar- macological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res. 54 : 5902-5910, 1994
 
11) Zaman, G. J., Flens, M. J., van Leusden, M. R. et al.: The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump. Proc. Natl. Sci. USA 91: 8822-8826, 1994
 
12) Zaman, G. J., Lankelma, J., van Tellingen, O. et al.: Role of glutathione in the export of compounds from cells by the multidrug-resistance-associated protein. Proc. Natl. Acad. Sci. USA 92: 7690-7694, 1995
PubMed
13) Gekeler, V., Ise, W., Sanders, K. H. et al.: The leukotriene LTD, receptor antagonist MK571 specifically modulates MRP associated multidrug resistance. Biochem. Biophys. Res. Commun. 208: 345-352, 1995
 
14) Stewart, A. J., . Canitrot, Y., Baracchini, E. et al.: Reduction of expression of the multidrug resistance protein (MRP) in human tumor cells by antisense phosphorothioate oligonucleotides. Biochem. Pharmacol. 51: 461-469, 1996
PubMed
15) Zaman,G.J.,Versantvoort,C.H.,Smit,J.J.et al.: Analysis of the expression of MRP,the gene for a new putative transmembrane drug transporter, in human multidrug resistant lung cancer cell lines. Cancer Res.53 :1747-1750, 1993
PubMed
16) Yun, J., Tomida, A., Nagata, K. et al.: Glucoseregulated stresses confer resistance to VP-16 in human cancer cells through a decreased expression of DNA topoisomerase II. Oncol. Res. 7: 583-590, 1995
 
17) Dimanche-Boitrel, M. T., Garrido, C. and Chauffert, B.: Kinetic resistance to anticancer agents. Cytotechnology 12: 347-356, 1993
PubMed
18) Brock, 1., Hipfner, D. R., Nielsen, B. S. et al.: Sequential coexpression of the multidrug resistance genes MRP and mdr1 and their products in VP-16 (etoposide)-selected H69 small cell lung cancer cells. Cancer Res. 55: 459-462, 1995
PubMed
P.91 掲載の参考文献
1) Fichtinger, S. A., van der Veer, J. I., Den, H. J. et al.: Adducts of the antitumor drug cis-diamminedichloroplatinum(II) with DNA: formation, identification, and quantitation. Biochemistry 24: 707-713, 1985
 
2) Eastman, A.: Reevaluation of interaction of cis-dichloro(ethylenediamine) platinum(II) with DNA. Biochemistry 25 : 3912-3915, 1986
PubMed
3) Knox, R. J., Friedlos, F。, Lydall, D. A. et al.: Mechanism of cytotoxicity of anticancer platinum drugs : evidence that cis-diamminedichloroplatinum(II) and cis-diammine-(1, 1-cyclobutanedicarboxylate) platinum(II) differ only in the kinetics of their interaction with DNA. Cancer Res. 46: 1972-1979, 1986
 
4) Hong, W. S., Saijo, N., Sasaki, Y. et al.: Establishment and characterization of cisplatin-resistant sublines of human lung cancer cell lines. lnt. J. Cancer 41 : 462-467, 1988
 
5) Morikage, T., Bungo, M., Inomata, M. et al.: Reversal of cisplatin resistance with amphotericin B in a nOn-small Cell lung cancer cell line. Jpn. J. Cancer Res. 82: 747-751, 1991
 
6) Bernal, S. D., Speak, J. A., Boeheim, K. et al.: Reduced membrane protein associated with resistance of human squamous carcinoma cells to methotrexate and cis-platinum. Mol. Cell. Biochem. 95: 61-70, 1990
PubMed
7) Kawai, K., Kamatani, N., Georges, E. et al.: Identification of a membrane glycoprotein overexpressed in murine lymphoma sublines resistant to cis-diamminedichloroplatinum(II). J. Biol. Cem. 265: 13137-13142, 1990
 
8) Ohmori, T., Morikage, T., Sugimoto, Y. et al.: The mechanism of the difference in cellular uptake of platinum derivatives in non-small cell lung cancer cell line (PC-14) and its cisplatin-resistant subline (PC -14/CDDP) . Jpn. J. Cancer Res. 84: 83-92, 1993
PubMed
9) Meister, A. and Anderson, M. E.: Glutathione (Review). Annu. Rev. Biochem. 52: 711-760, 1983
PubMed
10) Fujiwara, Y., Sugimoto, Y., Kasahara, K. et al.: Determinants of drug response in a cisplatin-resistant human lung cancer cell line. jpn. J. Cancer Res. 81: 527-535, 1990
 
11) Meister, A.: Glutathione deficiency produced by inhibition of its synthesis, and its reversal;applications in research and therapy (Review) . Pharmacol. Ther. 51: 155-194, 1991
PubMed
12) Ishikawa, T. and Ali, 0. F.: Glutathione-associated cis-diamminedichloroplatinum(II) metabolism and ATP-dependent efflux from leukemia cells. Molecular characterization of glutathione-platinum complex and its biological significance. J. Biol. Chem. 268: 20116-20125, 1993
 
13) Kurokawa, H., Ishida, T., Nishio, K. et al.: γ- glutamylcystein synthetase gene overexpression results in increased activity of the ATP-dependent glutathione S-conjugate export pump and cisplatin resistance. Biochecm. Biophys. Res. Commun. 216: 258-264, 1995
 
14) Kelley, S. L, Basu, A., Teicher, B. A. et al.: Overexpression of metallothionein confers resistance to anti-cancer drugs. Science 241: 1813-1815, 1988
 
15) Schilder, R. J., Hall, L, Monks, A. et al.: Metallothione in gene expression and resistance to cisplatin in human ovarian cancer. Int. J. Cancer 45: 416-422, 1990
 
16) Fraval, H. N., Rawlings, C. J. and Roberts, J. J.: Increased sensitivity of UV-repair-deficient human cells to DNA bound platinum products which unlike thymine dimers are not recognized by an endonu clease extracted from Microcicus luteus. Mutat. Res. 51: 121-132, 1978
 
17) Chu, G. and Chang, E.: Xeroderma pigmentosum group E cells lack a nuclear factor that binds to damaged DNA. Science 242: 564-567, 1988
 
18) Hansson, J., Grossman, L、, Lindahl, T. et al.: Complementation of the xeroderma pigmentosum DNA repair synthesis defect with Escherichia coli UvrABC proteins in a cell-free system. Nucleic Acids Res. 18: 35-40, 1990
 
19) Hwang, B. J. and Chu, G.: Purification and characterization of a human protein that binds to damaged DNA. Biochemistry 32: 1657-1666, 1993
 
20) Keeney, S., Wein, H. and Linn, S.: Biochemical heterogeneity in xeroderma pigmentosum complementation group E. Mutat. Res. 273: 49-56, 1992
PubMed
21) Kataoka, H. and Fujiwara, Y.: UV damage-specific DNA-binding protein in xeroderma pigmentosum complementation group E. Biochem. Biophys. Res. Commun. 175: 1139-1143, 1991
PubMed
22) Chu, G. and Chang, E.: Cisplatin-resistant cells express increased levels of a factor that rercognizes damaged DNA. Proc. Natl. Acad. Sci. USA 87: 3324-3328, 1990
 
23) van Duin, M., de Wit, J., Odijk, H. et al.: Molecular characterization of the human excision repair gene ERCC-1: cDNA cloning and amino acid homology with the yeast DNA repair gene RAD10. Cell 44: 913-923, 1986
PubMed
24) Dabholkar, M., Bostick, B. F., Weber, C. et al.: ERCCI and ERCC2 expression in malignant tissuesfrom ovarian cancer patients. J Natl. Cancer・lnst. 84: 1512-1517, 1992
 
25) Toney, J. H., Donahue, B. A., Kellett, P. J. et al.: Isolation of cDNAs encoding a human protein that binds selectively to DNA modified by the anticancer drug cis-diamminedichloroplatinum(II) (publishederratum appears in Proc. Natl. Acad. Sci. USA 87: 1625, 1990) . Proc. Natl. /1 cad. Sci. USA 86: 8328-8332, 1989
 
26) Bruhn, S. L, Pil, P. M., Essigmann, J. M. et al.: Isolation and characterization of human cDNA clones encoding a high mobility group box protein that recognizes structural distortions to DNA caused by binding of the anticancer agent cisplatin. Proc. Natl. Acad. Sci. USA 89: 2307-2311, 1992
PubMed
27) Pi1, P. M. and LipPard, S. J.: Specific binding of chromosomal protein HMGI to DNA damaged by the anticancer drug cisplatin. Science 256: 234-237, 1992
 
28) Lilley, D. M.: DNA-protein interactions. HMG has DNA wrapped up (news) . Nature 357: 282-283, 1992
PubMed
29) Brown, S. J., Kellett, P. J. and Lippard, S. J.: Ixr1, a yeast protein that binds to platinated DNA and confers sensitivity to cisplatin. Science 261: 603-605, 199330) Sancar, G. B.: DNA photolyases: physical properties, action mechanism, and roles in dark repair (Review) . Mutat. Res. 236: 147-160, 1990
 
30) Sancar, G. B. :DNA photolyases:physical properties, action mechanism, and roles in dark repair(Review). Mutat. Res. 236:147-160,1990
PubMed
31) Patterson, M. and Chu, G.: Evidence that xerodermapigmentosum cells from complementation group E are deficient in a homolog of yeast photolyase. Mol. Cell. Biol. 9: 5105-5112, 1989
 
32) Chu, G.: Cellular responses to cisplatin the roles of DNA-binding proteins and DNA repair. J. Biol. Chem. 269: 787-790, 1994
PubMed
33) Andoh, T., Ishii, K., Suzuki, Y. et al.: Characterization of a mammaliam mutant with a camptothecinresistant SNA. topoisomerase I. Proc. Natl. Acad. Sci. USA 84: 5565-5569, 1991
 
34) Kubota, N., Kanzawa, F., Nishio, K. et al.: Detectionof topoisomerase I gene point mutation inCPT-11 resistant lung cancer cell line. Biochem. Biophys. Res. Commun. 188: 571-577, 1992
 
35) Alton, P. A.: The role of DNA topoisomerase II in drug resistance. Br. J. Haematol. 85: 241-245, 1993
PubMed
36) Minato, K., Kanzawa, F., Nishio, K. et al.: Characterization of an etoposide-resistant human small-cell lung cancer cell line. Cancer Chem. Pharmacol. 26: 313-317, 1990a
 
37) Ohta, S., Nishio, K., Kubota, S. et al.: Characterization of a vindesine-resistant human small cell lung cancer cell line. Br. J. Cancer 68: 74-79, 1993
 
38) 0hta, S., Nishio, K., Kubota, N. et al.: Characterization of a taxol-resistant human small-cell lung cancer cell line. Jpn. J. Cancer Res. 85: 290-297, 1994
 

5 / 副作用対策

P.97 掲載の参考文献
1) Pizzo, P. A.: Considerations for the prevention of infectious complications in patients with cancer. Rev. Infect. Dis. Suppl. 7: S1551, 1989
 
2) Hughes, W. T., Smith, A., Bahn, F. et al.: Successful chemoprophylaxis for pneumocystis carinii pneumnitis. N Engl. J. Med. 297: 1419-1423, 1977
 
3) Karp, J. E., Merz, W. B, . Hendricksen, C. et al.: Oral norfloxacin for prevention of fram-negative bacterial infections in patients with acute leukemia and granulocytopenia : a randomized, double-blind, placebo-controlled tria1. Ann. Intern. Med. 106: 1-7, 1987
 
4) Ohno, R., Tomonaga, M., Kobayashi, T. et al.: Effect of granulocyte colony-stimulating factor after intensive induction therapy in relapsed or refractory acute leukemia. N. Engl. J. Med. 323: 871-877, 1990
PubMed
5) Parker, B. A., Anderson, J. R., Canellos, G. P. et al.: Dose escalation study of CHOP plus etoposide: with-out and with rhG-CSF in untreatment non-Hodgkin's lymphoma. Proc. ASCO 10: 283, 1991
 
6) Ohno, R., Hiraoka, A., Tanimoto, M. et al.: No increase of leukemia relapse in the newly diagnosed patients with acute myeloid leukemia who received granulocyte colony-stimulating factor for life-threatening infection during remission induction and consolidation therapy. Blood 81: 561-562, 1993
PubMed
7) De Pauw, B. E., Deresinski, S. C., Feld, R. et al.: Ceftazidime compared with piperacillin plus to-bramycin for the empiric treatment of fever in neutropenic patients with cancer. Ann. Intern. Med. 120: 834-844, 1994
 
8) Lok, S., Kaushausky, K., Holly, R. D. et al.: Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo. Nature 369 : 565-568, 1994
 
9) 浦部晶夫, 溝口秀昭, 高久史麿ほか: 遺伝子組換えヒトエリスロホエチンの骨髄異形成症候群に伴う貧血に対する第II相臨床試験. 臨床血液34: 928-936, 1993
 
10) 浦部晶夫, 溝口秀昭, 高久史麿ほか: 遺伝子組換えヒトエリスロポエチンの多発性骨髄腫に伴う貧血に対する第II相臨床試験. 臨床血液34: 919-927, 1993
 
P.104 掲載の参考文献
1) Denis, J. M., Dose, M. A., Loprinzi, C. L. et al.: Inhibition of fluorouracil induced stomatitis by oral cryotherapy. 1. Clin. Oncol. 19: 449-452, 1991
 
2) Howell, S. B., Wung, W., Taetle, R. et al.: Modulation of 5-fluorouracil toxicity by allopurinol in man. Cancer 48: 1281-1289, 1981
PubMed
3) Gabrilove, J. L., Jakubowski, A., Scher, H. et al.: Eeffect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell cacinoma of the urothelium. N. Engl. J. Med. 318: 1414-1422, 1988
 
4) Rand, K. B., Kramer, B. and Johson, A. C.: Cancer chemotherapy associated symptomatic stomatitis role of herpes simplex virus. Cancer 50: 1262-1265, 1982
 
5) Solomon, M. A.: Oral sucralfate suspension for mucositis. N. Engl. J. Med 315: 459-460, 1986
PubMed
6) Epstein, J. B., Stevenson-Moore, P., Jackson, S. et al.: Prevention of oral mucositis in radiation therapy: a cotrolled study with benzydamine hydrochloride rinse. Int. J. Radiat. Oncol. Biol. Phys. 16: 1571-1575, 1989
 
7) 石井準之助, 中西孝一, 島田桂吉: 放射線口内炎に対するサルコートによる治療経験. 癌と臨床 36: 66-70, 1990
 
8) Borison, H. L. and Wang, S. C.: Physioligy and pharmacology of vomiting. Pharmacol. Rev. 5: 193-230, 1953
 
9) 木村英三, 新美茂樹, 渡辺明彦ほか: CDDPを含む癌化学療法施行時の悪心・嘔吐に対する塩酸Azasetron持続点滴法の検討. 癌と化学療法23: 477-481, 1996
 

6 / 薬物療法とQOL

P.111 掲載の参考文献
1) 抗悪性腫瘍薬の臨床評価方法ガイドライン作成に関する研究班: 抗悪性腫瘍薬の臨床評価方法ガイドライン (薬新薬第9号, 平成3年2月4日, 厚生省薬務局医薬品課長通知) . 1991
 
2) Johnson, J. R. and Temole, R.: Food and Drug Administration requirements for approval of new anticancer drugs. Cancer Treat. Rep. 69: 1155-1157, 1985
 
3) Moinpour, C. M., Feigel, P., Metch, B. et al.: Quality of life and points in cancer clinicals trials: review and recommendations. J. Natl. Cancer Inst. 81: 485-495 1989
 
4) 太田和雄: QOLからみた癌化学療法の諸問題.癌治療とQOL 1(2): 3-5, 1992
 
5) 栗原稔: 癌化学療法とQOL評価法. 癌治療とQOL 1(2): 6-9, 1992
 
6) 栗原稔: 進行胃癌化学療法のプロトコール作成-5': DFUR+CDDPをモデルとして-. 癌と化学療法 20 : 2447-2453, 1993
Medical*Online
7) Slevin, M. L., Plant, H., Lynch, D. et al.: Who shoud measure quality of life the doctor or patient?Br. J. Cancer 57: 109-112, 1988
PubMed
8) Donovan, K., Sanson-Fisher, R. W. and Redman, S. et al.: Measuring quality of life in cancer patients. J. Clin. Oncol. 7: 959-968, 1989
PubMed
9) De Haes J. C. J. M. et al.: The quality of life of cancer patients: a review of literature. Soc. Sci. Med. 20: 809-817, 1989
 
10) Aaronson, N. K。, Bullinger, M., Ahmedzai, S. et al.: A modular approach to quality of life assessment in cancer clinical trials. Recent Reszalts Cancer Res. 111 : 231-249, 1988
 
11) Schipper, H. and Levitt, M.: Measuring quality of life : risk and benefits. Cancer Treat. Rep. 67: 1115-1123, 1985
 
12) 栗原稔, 清水弘之, 坪井康次ほか: がん薬物治療プロトコールにおけるQOL評価. CRC 1: 174-181 1992
 
13) 栗原稔, 江口研二, 下妻晃二郎ほか: がん薬物療法におけるQOL調査票. 日癌治28: 1140-1144, 1993
 
14) Lorish, C. D. and Maisia, K.: The face scale: a brief nonverbal method for assessing patient mood. Arthritis Rheum. 29: 906-909, 1986
 
15) Shokei, 0., Nakamura, H. and Kurihara, M.: QOL assessment for liver cancer patient have a therapy. In: Second International Congress of Psycho-Oncology (Abst.), 1995, pp. 69-199
 
16) Lindrey, C. M., Hirsh, J., 0: Neill, D. et al.: Quality of life consequences of chemotherapy-induced emesis. Qual. Life Res. 1: 331-340, 1992
 
17) 正慶修, 栗原稔, 中村浩之: 心理教育的アプローチを必要とした進行癌患者の一例. 消化器心身医学 2: 58-64, 1995
 
18) 鈴木紀彰, 栗原稔, 中村浩之: 癌のサポートテラピー, QOL評価の実際, 癌治療における副作用対策とサポートテラピー, 国際医書出版, 東京, 1994, pp. 118-127
 

7 / 遺伝子治療

P.116 掲載の参考文献
1) Clinical protocol. Cancer Gene Ther. 3: 58-69, 1996
 
2) Friedmann, T.: Human gene therapy-an immature genie, but certaily out of the bottle. Nat. Med. 2: 144-147, 1996
 
3) Blase, R. M., Culver, K. W., Miller, A. D. et al.: T lymphocyte-directed gene therapy for ADA-SCID: Initial trial results after 4 years. Science 270: 475-480, 1995
 
4) Knowles, M. R., Hohneker, K. W., Zhov, Z. et al.: A controlled study of adenoviral-mediated gene transfer in the nasal epithelium of patients with cystic fibrosis. N. Engl. J. Med. 333: 823-831, 1955
 
5) Muligan, R. C.: The basic science of gene therapy. Science 260: 926-932, 1993
 
6) Unterhuber, R.: Germany playing"catch-up"in gene therapy. Nat. Med. 2: 136, 1996
 
7) Marshall, E.: Gene therapy's growing pains. Science 269: 1050-1055,
PubMed
8) Rosenberg, S. A.: The development of new cancer therapies on the molecular identification of cancer regression antigens. Cancer J. 1: 90, 1995
 
9) Kawakami, Y., Eliyahu, S., Delgado, C. H. et al.: Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltration into tumor. Proc. Natl. Acad. Sci. USA 91: 3515-3519, 1994
PubMed
10) 高後裕, 藤本佳範: 遺伝子治療の動物実験. 癌の新しい遺伝子診断と治療, 医薬ジャーナル社, 大阪, 1995, pp. 197-213
 
P.121 掲載の参考文献
1) 河上裕: 遺伝子治療はどこまで進んだか, アメリカでの現状と癌治療への応用. Medicina 30: 2407-2417, 1993
 
2) Kawakami, Y., Robbins, P. F., Wang, R. F. et al.: Identification of tumor regression antigens in Melanoma. In: Important Advances in Oncology 1996, Lippincott-Raven, Philadelphia, 1996, pp. 3-21
 
3) Rosenberg, S. A.: The development of new cancer therapies based on the molecular identification of cancer regression antigens. Cancer J. Sci. Am. 1: 90-100, 1995
PubMed
4) Van Pel, A., van der Bruggen, P., Coulie, P. G. et al. Genes coding for tumor antigens recognized by cytolytic T lymphocytes. immunol. Rev. 145: 229-250, 1995
PubMed
5) Hsu, F. J., Benike, C., Fagnoni, F. et al.: Vaccination of patients with B cell lymphoma using autologous antigen pulsed dendritic cells. Nature Med. 2: 52-58, 1996
PubMed
6) Cheever, M. A., Disis, M. L, Bernhard, H. et al.: Immunity to oncogenic proteins. 145: 33-59, 1995
PubMed
7) Finn, 0. J., Jerome, K. R., Henderson, R. A. et al.: MUC-1 epithelial tumor mucin based immunity and cancer vaccines. Immunol. Rev. 145: 61-89, 1995
 
8) Tsang, K. Y., Zaremba, S., Nieroda, C. A. et al.: Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J. Natl. Cancer Inst. 87: 982-990, 1995
PubMed
9) Rosenberg, S. A.: The immunotherapy and gene therapy of cancer. J. Clin. Oncol. 10: 180-199, 1992
 
10) Rosenberg, S. A.: Gene therapy of cancer. JAMA 268 : 2416-2419, 1992
PubMed
11) Hwu, P., Shafer, G. E., Treisman, J. et al.: Lysis of ovarian cancer cells by human lymphocytes redirect ed with a chimeric gene composed of an antibody variable region and the Fc receptor γ-chain. J. Exp. Med. 178: 361-336, 1993
 
12) Fearon, E. R., Pardoll, D. M., Itaya, T. et al.: Interleukin 2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 60: 397-403, 1990
PubMed
13) Dranoff, G., Jaffee, E., Lazenby, A. et al.: Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. USA 90: 3539-3543, 1993
PubMed
14) Simmons, J.: Phase I study of non-replicating autologous tumor cell injections using cells prepared with or without GM-CSF gene transduction in patients with metastatic renal cell carcinoma. Hum. Gene Ther. 6: 347-368, 1995
PubMed
15) Lotze, M. T.: Gene therapy of cancer: a pilot study of IL4 gene modified fibroblasts admixed with autologous tumor to elicit an immune response. Hum. Gene Ther. 5: 41-56, 1994
 
16) Chen, L, McGowan, P., Ashe, S. et al.: Tumor immunogenicity determines the effect of B7 costimulation on T cell mediated tumor immunity. J. Exp. Med. 179: 523-532, 1994
 
17) Nabel, G. J., Nabel, E., Yang, Z. Y. et al.: Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans. Proc. Natl. Acad. Sci. USA 90: 11307-11311, 1993
PubMed
18) Zhai, Y., Yang, J., Kawakami, Y. et al.: Antigenspecific tumor vaccines: development and characterization of recombinant adenoviruses encoding MART1 or gp100 for cancer therapy. J. Immunol. 156: 700-710, 1996
PubMed
19) Conry, R., LoBuglio, A. F., Kantor, J. et al.: Immuneresponse to a carcinoembryonic antigen polynucleotide vaccine. Cancer Res. 54: 1164-1168, 1994
 
20) Restifo, N. P., Marincola, F. M., Kawakami, Y. et al.: Loss of functional beta2-microglobulin in metastatic melanomas from five patients receiving immunotherapy. J. Natl. Cancer Inst. 88: 100-108, 1996
PubMed

書評

最近チェックした商品履歴

Loading...